Loading
A phase 2 trial of SKB264 in ovarian cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., active and no longer recruiting.
Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC is a phase 2 interventional study registered as NCT07341100 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 20 participants enrolled, started 2026-01-16 and due to reach its primary completion in 2028-01. Interventions recorded: SKB264 and Clarithromycin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/